Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
9
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,777.90 | 50.80 | -0.58% |
| CAC 40 | 7,866.98 | 100.27 | 1.29% |
| DAX 40 | 24,499.74 | 292.83 | 1.21% |
| Dow JONES (US) | 44,240.76 | 165.60 | -0.37% |
| FTSE 100 | 8,872.76 | 18.58 | 0.21% |
| HKSE | 23,892.32 | 255.75 | -1.06% |
| NASDAQ | 20,418.46 | 5.95 | 0.03% |
| Nikkei 225 | 39,821.28 | 132.47 | 0.33% |
| NZX 50 Index | 12,768.61 | 90.41 | -0.70% |
| S&P 500 | 6,225.52 | 4.46 | -0.07% |
| S&P/ASX 200 | 8,538.60 | 52.10 | -0.61% |
| SSE Composite Index | 3,493.05 | 4.43 | -0.13% |